Radiation exposure during nuclear cardiology procedures has received much attention and has prompted citations for radiation reduction. In 2010, the American Society of Nuclear Cardiology recommended reducing the average patient study radiation exposure to <9 mSv in 50% of studies by 2014. Cardiac positron emission tomography (PET) for myocardial perfusion imaging (MPI) has emerged within recent years, but current radiation exposure in cardiac nuclear PET laboratories is unknown. This study evaluated current reported patient radiation exposure from nuclear laboratories in the United States applying for Intersocietal Accreditation Commission accreditation for MPI using single photon emission computed tomography (SPECT) or PET.
Desiderio et al; Radiation Exposure of Cardiac PET and SPECT MPI C ardiac nuclear myocardial perfusion imaging (MPI) has demonstrated excellent value for diagnosis and risk stratification of patients with known or suspected coronary artery disease. 1 The mainstay of these tests is the cardiovascular stress test with MPI using single-photon emission computed tomography (SPECT). Despite the clinical value, these procedures are associated with radiation exposure. The as-low-as-reasonably-achievable principle has been widely applied to medical procedures requiring exposure to ionizing radiation. Because of societal concerns and optimal patient care, the American Society of Nuclear Cardiology (ASNC) published an information statement recommending the average radiation exposure for cardiac nuclear imaging studies to be <9 mSv in 50% of studies in a given laboratory by the year 2014 2 . It is unknown whether clinical nuclear laboratories comply with these recommendations; however, database analysis from laboratories seeking accreditation from the Intersocietal Accreditation Commission (IAC) in the 2 years following the ASNC recommendations and before the 2014 timeframe revealed nonadherence to these practice goals. 3 Jerome et al 3 reported <2% of SPECT laboratories in the IAC database had achieved ASNC radiation goals, and the mean radiation exposure was 14.9 mSv. Additionally, 10% of laboratories still produced high radiation studies >20 mSv. These data suggest nuclear cardiology laboratories in the United States are not taking full advantage of currently available radiation reduction strategies. [4] [5] [6] [7] Recently, there has been an increase in the utilization of cardiac positron emission tomography (PET) studies in the United States. A growing body of literature demonstrates cardiac PET imaging produces high-quality images with high diagnostic accuracy for the detection of obstructive coronary disease at low radiation exposures combined with fast procedures. Studies from academic institutions performing cardiac MPI with PET imaging have reported radiation exposure ranging from 2.5 to 5 mSv for rest/stress studies. 8 Currently, there are no data on cardiac PET radiation exposure on a national basis in clinical laboratories. In addition, the previous report of SPECT radiation exposure was before the year recommended by ASNC for radiation dose reduction by 2014. The purpose of this study was to examine recent radiation exposure reported by cardiac PET and SPECT MPI from the IAC database of laboratories applying for accreditation or reaccreditation.
METHODS
This was an analysis of nuclear cardiology radiation exposure reported by laboratories submitted to the IAC for the purpose of nuclear cardiology laboratory accreditation or reaccreditation. Applying nuclear cardiology laboratories across the United States were required to submit 3 to 5 representative cases, which contained at least 1 normal study. The study examined data from 2015 for SPECT and 2013 to 2015 for PET. Data and study materials will not be made available to others for the purpose of replicating the results because these data were part of an investigator-initiated grant from the IAC. Approval from an institutional review board was not required because no patient data or private or identifiable facility information was collected, and the results were reported in aggregate.
Imaging data included patient factors (eg, age and sex but not weight), radiopharmaceutical, and camera age and type. Facility data included number of physicians, Certification Board of Nuclear Cardiology status of the medical director, number of Certification Board of Nuclear Cardiology certified physicians, number of technologists, type of facility, annual volume of nuclear cardiology exams performed, geographic region of the laboratory as defined by the US Census bureau (Northeast: Connecticut, Delaware, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, District of Columbia, Kentucky, Florida, Georgia,
CLINICAL PERSPECTIVE
Radiation exposure during nuclear cardiology procedures has received much attention and has prompted numerous citations for radiation reduction. In 2010, the American Society of Nuclear Cardiology recommended reducing the average patient study radiation exposure to <9 mSv in 50% of single-photon emission computed tomography (SPECT) studies by 2014. Radiation exposure of SPECT perfusion imaging following this recommendation deadline has not yet been evaluated. Cardiac positron emission tomography (PET) for myocardial perfusion imaging has emerged within recent years, but current radiation exposure in cardiac nuclear PET laboratories is unknown. Herein, we provide a comprehensive analysis of myocardial perfusion imaging data from the Intersocietal Accreditation Commission database of accredited laboratories. Radiation exposure of cardiac PET studies was ≈3.6 mSv per study, whereas SPECT was ≈14.6 mSv. Overall, 100% of PET laboratories were able to achieve the American Society of Nuclear Cardiology goal of <9 mSv of radiation exposure per study compared with 2.6% of SPECT laboratories. Despite well-established methods, most clinical laboratories in the United States are failing to reduce radiation exposure during SPECT myocardial perfusion imaging and have not appreciably changed from a previous study. PET is a clinically used modality, which invariably provides high diagnostic accuracy at a fraction of the radiation exposure. Desiderio 
Radiation Exposure Calculation
Radioisotopes for this study included thallium (Tl-201) and technetium (Tc-99m) for SPECT and rubidium-82 (Rb-82) and ammonia N-13 (NH3) for PET. The repository contained reported amounts of radioisotope (in millicuries or megabecquerels) for both the stress and rest studies. 
Statistical Analysis
Initial evaluation of both SPECT and PET data included a description of the isotope, type of study, and estimated average radiation exposure for each laboratory based on mean study dose. Further categorical comparisons of radiation exposure and US geographic region (by the US Census bureau data), type of practice, and laboratory volume were made. Using the Kolmogorov-Smirnov test, most parameters (including radiation dose) had non-normal distributions. Thus, categorical variables are presented as percentages and compared using χ 2 statistics and continuous variables are presented as medians (25th-75th quartile) and compared using Mann-Whitney U test. When >2 groups were compared, a Kruskal-Wallis 1-way ANOVA test was performed; following a significant result, the Dunn post hoc test was used to evaluate pairwise comparisons. Correlation of the radiation exposure to individual laboratory parameters was performed by Spearman-ρ correlation. All analyses were conducted at the laboratory level, unless otherwise specified. A P value <0.05 was chosen to represent statistical significance for all analyses, which were conducted using SPSS, version 25.0 (IBM Corporation, Chicago, IL).
RESULTS
The evaluation of IAC laboratories included 665 SPECT facilities applying during 2015 and 111 PET laboratories applying between the years 2013 and 2015. Three thousand and sixty-seven SPECT and 532 PET studies were submitted. Laboratory characteristics are presented in Table 1 . The majority of SPECT laboratories were from outpatient offices (77.1%) with a smaller percentage from inpatient facilities (13.4%). PET laboratories followed a similar distribution. The US region with the highest percentage of applicants was the South (SPECT, 47.8%; PET, 66.7%), whereas the lowest was from the West (SPECT, 9.9%) and Midwest (PET, 8.1%). SPECT equipment was slightly newer than PET (median, 11 years versus 14 years, respectively). Overall, annual SPECT and PET laboratory volumes were similar (median, 800 versus 825 cases per year, respectively).
In the laboratories applying for PET accreditation, the calculated median effective radiation dose was 3.7 (3.2-4.1) mSv, which consisted of both Rb-82 (n=521; estimated radiation exposure, 3.7 [3.2-4.1] mSv) and NH3 (n=11; estimated radiation exposure, 4.2 [2.8-5.5] mSv) for MPI ( Table 2 ). The data are illustrated in Figure 1A. The median cardiac PET radiation dose was uniform across all geographic regions (Kruskal-Wallis P=0.419; Figure 2 ) and laboratory types (Kruskal-Wallis P=0.105; Figure 3 ). There was also no significant correlation between laboratory PET volume and median effective radiation dose (Spearman-ρ P=0.081).
For the laboratories applying for SPECT accreditation in 2015, the calculated median effective radiation (Table 3 ). The majority of cases used a one day, rest/stress technetium protocol (85.3%) which yielded a mean effective radiation dose of 12.8±1.8 mSv. There was no significant difference in radiation dose between those laboratories using sestamibi and tetrofosmin. The median radiation dose varied among the other protocols, as illustrated in Table 3 , ranging from 8.7 (3.8-9.2) mSv in the 0.4% of cases that used the Tc-99m stress-only protocol to 33.1 (30.5-34.4) mSv in the 7.1% of cases that used the rest Tl-201/stress Tc-99m dual-isotope protocol. There was significant variability in SPECT radiation exposure across the United States (Kruskal-Wallis P=0.008; Figure 2 ). The median (±interquartile range) effective radiation dose was significantly higher in the South region (12.9±2.6 mSv) than the Northeast (12.7±1.6 mSv; Dunn P=0.007), although likely not a clinically relevant difference. No variation in radiation exposure was seen according to laboratory types (Kruskal-Wallis P=0.706; Figure 3 ).
Overall PET and SPECT radiation exposure and variability is illustrated in Figure 4 . In this histogram evaluation, radiation exposure during cardiac PET procedures was uniformly lower with less variation in comparison with SPECT, and all were below ASNC recommendations. In contrast, of the 665 SPECT laboratories, only 2.6% of all studies were able to achieve this recommendation. Univariate analysis demonstrated geographic region and number of physicians significantly differed in the likelihood of having a mean effective radiation dose of <9 mSv (Table 4 ). Most notably, there was no effect of laboratory volume or concomitant cardiac PET application on radiation exposure.
Nuclear laboratories that applied for both PET and SPECT accreditation in 2015 (n=32) were also examined for radiation exposure. These dual PET/SPECT laboratories are unique in that select patients who are known to require higher doses of SPECT radiopharmaceutical to achieve adequate image quality are instead able to undergo PET imaging. The median SPECT radiation exposure in the dual PET/SPECT laboratories was 12.4 (10.3-14.2) mSv. Seven (≈22%) of these dual PET/ SPECT laboratories used thallium protocols, and only 1 laboratory submitted stress-only data.
To determine whether the submitted radiation exposure reflected usual laboratory practices, we compared the protocol dose and the study-reported dose for a sample of laboratories. Using a random subset of the SPECT data (91 laboratories), the median (25th-75th quartile) rest/stress technetium-only protocol dose stated in the application was 40 (40-44) mCi. The reported radiation dose from individually submitted data from a subset of SPECT data (108 laboratories, 492 studies) was 32.7 (30.1-34.4) mCi for rest/ stress technetium-only studies. For a subset of PET laboratories (103 laboratories), the median (25th-75th quartile) protocol total dose was 90 (90-100) mCi. The reported radiation dose from a subset of the PET laboratories (108 laboratories, 521 studies) was 90 (71.4-103.1) mCi. A selection of 94 SPECT laboratories was taken at random to evaluate differences in radiation exposure between weight-based and fixed-dose protocols. The median (25th-75th quartile) total study dose used in 104 studies from 26 laboratories that used weight-based protocols was 41.4 (36.1-44.1) mCi. The median total study dose used in 
The recent temporal trends in radiation exposure and reduction strategies were examined using IAC data from years 2012, 2013, and 2015 for both SPECT and PET applications, presented in Table 5 . There were no significant differences in the median radiation exposure for any of the SPECT protocols. Overall, the percentages of these studies did not appreciably change between 2012 and 2015. In contrast, there was a significant reduction of median PET radiation exposure 
DISCUSSION
This study was conducted to assess contemporary reported radiation exposure from cardiac PET and SPECT MPI throughout the United States. Using the IAC database of laboratories applying for accreditation of cardiac PET and SPECT, MPI studies were evaluated for radiopharmaceutical protocol and reported patient radiation exposure. We report, for the first time, median radiation exposure from 111 cardiac PET laboratories to be 3.7 mSv (range, 1-6 mSv) per study. These data represent laboratories using both Rb-82 and NH3 with similar findings. There was no geographic variation of cardiac PET MPI radiation exposure. In contrast, our study found the median radiation exposure for SPECT MPI to be 12.8 mSv (range, 2-41 mSv) per study. Only 2.6% of SPECT laboratories met ASNC goals. The SPECT findings from 2015 do not substantially differ from the previous report by Jerome et al 3 from 2012 to 2013. Temporal trends in radiation exposure for nuclear MPI procedures have demonstrated no significant change in overall radiation exposure for SPECT MPI in the United States (Table 5 ). Stress-only imaging remains underutilized, and thallium remains present in a substantial amount of studies (8.4%). In contrast, cardiac PET MPI utilization has increased since 2012 and has resulted in significantly reduced radiation exposure in 2015. This reduction is likely because of increased use of 3-dimensional (3D) imaging systems.
These radiation estimates from the IAC database are supported by studies from the International Atomic Energy Agency (IAEA) Nuclear Cardiology Protocols Study (INCAPS) investigators who report similar estimates of SPECT radiation exposure but with increased prevalence of stress-only imaging in 50 selected nuclear laboratories in the United States. [11] [12] [13] We evaluated predictors of low radiation dose in SPECT MPI and found few. The only predictor of lower radiation exposure was geographic region and number of physicians (Table 4) . Importantly, concomitant cardiac PET in the same laboratory did not predict lower radiation exposure for SPECT studies. This suggests practices choosing to perform PET MPI do so for reasons other than radiation exposure and perhaps are drawn to cardiac PET MPI for superior image quality, shorter protocols, or the ability to perform other cardiac PET protocols. 14 This study represents the first evaluation of cardiac PET MPI radiation exposure from multiple clinical laboratories. The findings are consistent with reports from previous single-center studies and a smaller multicenter database. 8, 11, 13, 15 The primary cardiac PET agent in accredited laboratories is Rb-82 (97%). Previous data in normal subjects demonstrate an average radiation exposure of 0.9 mSv/20 mCi for Rb-82. 16 This translates to 2 to 6 mSv per study, depending on whether a 2-dimensional (2D) or 3D system is used. 8 Case et al 8 estimated achievable rubidium radiation exposure levels of 2 mSv for 3D systems and 4 mSv for 2D systems. The single-center data of Hunter et al 15 confirmed these radiation exposure levels. Data from selected nuclear laboratories in the United States during the year 2013 report similar findings of PET radiation exposure. 12 The reported 3.7 mSv for rubidium doses suggests most laboratories in the IAC database are using 2D systems. Thus, as more 3D PET systems become available, one can anticipate further reductions in cardiac PET radiation exposure in the future. A small number of IAC laboratories used ammonia as the cardiac PET tracer. The findings of 4.2 mSv per study are consistent with the literature. 8, 9, [11] [12] [13] 15 Although the cardiac PET data are encouraging, it is also possible to further reduce cardiac PET radiation exposure. In a recent evaluation of cardiac PET techniques, Case et al 8 described additional means of reducing patient radiation in PET MPI. These include moving from 2D to 3D systems and elimination of unnecessary second attenuation correction studies. Clinical nuclear laboratories in Europe report mean PET (inclusive of FDG, ammonia, and rubidium) radiation exposure estimates of 2.6 mSv. [11] [12] [13] Indeed, data from Hunter et al 15 suggest using these strategies routinely result in an average cardiac PET patient radiation exposure of 1.6 mSv, which is substantially lower than reported in the present study. Despite the low percentage of SPECT laboratories achieving ASNC goals, techniques are available to reduce radiation exposure and do not necessarily require purchase of new equipment. These approaches can be separated into 3 categories: protocol selection, software upgrades of existing systems, and finally new camera technologies. 1, [12] [13] [14] [15] [16] [17] [18] [19] Reducing patient radiation exposure by protocol selection could easily be addressed by tracer choice (avoidance of thallium and dual-isotope protocols), weight-based dosing, and the use of stress-only (or stress first) approaches. The IAC database demonstrates that even in 2015, 8.4% of patient studies were using thallium in MPI protocols, despite ASNC recommendations against this practice.
2,4,7 Data supporting the stress-first/stress-only concept demonstrate only 8% to 15% of all SPECT MPI studies are positive for ischemia, 17 making stress-only imaging in a substantial percentage of patients feasible. Stress-only imaging has been recommended by professional societies for many years as a method of reducing radiation exposure by as much as 30% to 70%, but in 2015, <0.5% of IAC laboratories used this practice. 18 Evaluation of radiation exposure in patients undergoing 2-day protocols was higher than those undergoing same-day protocols ( Table 3 ). The most likely explanation for this finding is laboratories chose 2-day protocols in larger patients to maintain high image quality. This observation was noted previously by Jerome et al 3 also with IAC data. Dose reduction software is now available for many existing camera systems. Such add-on software upgrade packages provide excellent image quality with substantially lower doses of radiation to patients can be achieved without major expense. In the present study, camera age was found to be 11 years on average (Table 1 ) and would be appropriate for software upgrades. New camera technology (cadmium-zinc telluride) require markedly lower radiation doses without sacrificing diagnostic accuracy or image quality 19 but were infrequently used in laboratories applying for accreditation in 2015.
These radiation reduction practices for SPECT are clinically feasible and have been implemented elsewhere. Thompson et al 20 evaluated >18 000 SPECT studies from a single health system during a 7-year period over the time of the ASNC recommendation. Their data demonstrated a significant reduction in mean radiation exposure by 60% during 7 years through implementation of low-dose protocols (such as stress-only imaging), elimination of thallium, and the utilization of new camera technology. The mean radiation exposure per study fell dramatically from 17.9 mSv before the recommendations to 7.2 mSv afterward. The median reported dose was <3 mSv, which is well below the ASNC recommendation. Data from the European INCAPS registry suggest the United States is trailing behind radiation reduction in MPI. European SPECT laboratories report radiation exposure of ≈8.7 mSv per study. Thallium imaging was used in <3% of patient studies. Additionally, stress-only protocols were performed in ≈20% of patient studies. Overall, implementation of these radiation-reduction strategies in Europe has translated to ≈59% of nuclear laboratories achieving the ASNC-recommended radiation exposure goals. [11] [12] [13] The continued use of thallium imaging in the United States is linked to geographic considerations. Rural areas of the United States may rely on thallium rather than technetium because of accessibility issues and longer half-life. Additionally, certain insurance and Medicare carriers in regions of the United States reimburse thallium at a rate higher than the cost of the tracer, thus providing a monetary incentive to continue use of this higher radiation exposure tracer. With these considerations, the IAC standards have become more stringent regarding the utilization of thallium in nuclear imaging, and thallium is strongly discouraged pending individualized justification. 21 The impact of radiation exposure to both the patient and healthcare workers in medical imaging is largely conjecture based on cancer risk estimation at the exposure levels seen in modern medical imaging procedures thus making the <9 mSv recommendation somewhat arbitrary. However stochastic effects of repeated medical radiation exposure (chest radiographs, computed tomography, and angiography) culminated over a lifetime combined with increased background radiation incur an unknown but omnipresent risk. 22 Our data identify a significant opportunity to reduce radiation exposure in a substantial number of SPECT studies performed in the United States each year. Recent studies have evaluated cellular changes that occur during exposure to ionizing radiation. Lee et al 23 demonstrated radiation exposure equivalent to SPECT MPI induces a variable response in cell signaling pathways with only a small subset of patients revealing evidence of DNA damage. Data from the computed tomography literature have demonstrated activation of genes involved in cell repair and apoptosis occur when cells are exposed to radiation levels exceeding 7.5 mSv. 24 These data support a radiation exposure goal that is lower than current ASNC recommendation. Indeed, cardiac PET and low radiation protocol SPECT are able to achieve a low level of radiation exposure, which is unlikely to induce cell cycle changes. Recent analysis of adult congenital heart disease patients has demonstrated increased incidences of cancers with repeated exposure to lowdose ionizing radiation after controlling for factors such as cigarette smoking, age, sex, and comorbidities. 25 Despite the uncertainty, the principle of as low as reasonably achievable remains a guiding tenant and common goal in health care to mitigate all means of patient and provider risk, which has been echoed by ASNC position paper.
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LIMITATIONS
This analysis relies solely on data from cases submitted to the IAC by laboratories seeking accreditation or reaccreditation and may not represent radiation exposure from all studies in a given laboratory. Although another accreditation organization exists, it is expected that the IAC database reflects the distribution of the United States. Additionally, submitted data are self-selected as best-case studies from each laboratory and are more likely to be biased toward optimal quality studies. The subanalysis suggests that study radiation exposure follows closely with the laboratory protocols, and thus the submitted data represent actual laboratory practices. It should also be noted that radiation exposure is an approximation. Radiation dose is computed from the amount of radiotracer which is estimated for SPECT or directly recorded from the delivery system for PET. The effective dose conversion factors are approximations as well. In the current study, resting state effective dose calculations are performed to provide consistency for all types of pharmacological stress agents and varying levels of exercise during clinical nuclear stress testing procedures. PET camera type (2D or 3D) was also not recorded and so PET data simply represent the conglomerate of PET MPI studies in the United States. The additional radiation exposure incurred by attenuation correction from radiographs or other sources was not recorded by the IAC data collection tool and may represent a substantial source of ionizing radiation. Finally, this analysis exclusively evaluated cardiac PET and SPECT MPI studies. Nuclear cardiology protocols have now expanded beyond MPI for both SPECT and PET (Tc-99m pyrophosphate for amyloid imaging, meta-iodobenzylguanidine for cardiac sympathetic imaging, fluorodeoxyglucose for metabolic studies, etc); however, these tests are not as widespread or common as MPI imaging studies across the United States, and data are limited.
CONCLUSIONS
Based on the IAC database, median radiation exposure from cardiac PET MPI procedures is estimated at 3.7 mSv per study in clinical laboratories in the United States. This level of radiation exposure was uniformly low throughout the United States, and all cardiac PET MPI laboratories were well below ASNC-recommended radiation goals. In contrast, SPECT MPI results in mean radiation exposure of 12.8 mSv per study. Only 2.6% of SPECT MPI laboratories are able to achieve the ASNC-recommended radiation goal. Our data stand in agreement with the 2017 ASNC recommendation for PET imaging being the preferred modality for pharmacological MPI testing. For patients who require functional testing, careful attention to radiation reduction techniques can substantially reduce the radiation exposure incurred by SPECT MPI.
